Neuroendocrine neoplasms (NEN) are rare tumors that exhibit a variety of morphological, functional and behavioral characteristics.[@b1] The World Health Organization (WHO) has proposed a grading system for NEN that divides them into three categories based on proliferation as follows: (i) neuroendocrine tumor (NET) (G1) with a mitotic count of \<2/10 high power fields (HPF) and/or a Ki-67 index of ≤2%; (ii) NET (G2) with a mitotic count of 2--20/10 HPF and/or a Ki-67 index of 3--20%; and (iii) neuroendocrine carcinoma (NEC) with a mitotic count of \>20/10 HPF and/or a Ki-67 index of \>20%.[@b2] Among the three categories, NEC is a poorly differentiated, high-grade malignant tumor, previously termed poorly differentiated neuroendocrine carcinoma (PDNEC), including small-cell carcinoma (SCC) and large-cell NEC. The primary sites of NEC are varied in many organs, with NEC arising in the digestive system accounting for 20--68% of cases with extra-pulmonary NEC.[@b3]--[@b7]

In treating advanced extra-pulmonary NEC, guidelines recommend chemotherapy regimens, which are suitable for small-cell lung carcinoma (SCLC).[@b8]--[@b10] Therefore, platinum-containing regimens, such as etoposide plus cisplatin (EP), are commonly used for NEC arising from the digestive system in clinical practice worldwide and irinotecan plus cisplatin (IP) is commonly adopted in Japan. However, no randomized controlled trial has been conducted previously and retrospective reports have been limited in scope and number.[@b11]--[@b15] Therefore, we conducted a multicenter retrospective study on the outcomes of systemic chemotherapy for advanced NEC of the digestive system to obtain useful information to prepare for a future clinical trial.

Materials and Methods
=====================

The selection criteria were as follows: (i) a histologically proven NEC such as PDNEC, SCC, mixed endocrine-exocrine carcinoma with a PDNEC component (MEEC), or a neuroendocrine tumor with a rapidly progressive clinical course (clinically-diagnosed NEC); (ii) a primary tumor arising in the digestive system (gastrointestinal tract \[GI\] or hepato-biliary-pancreatic system \[HBP\]); (iii) an unresectable or recurrent disease treated with systemic chemotherapy, which was initiated between April 2000 and March 2011; and (iv) no prior treatment, except for surgical resection. Data were collected from the medical records of patients at 23 institutions in Japan using a standardized data collection form. This study was approved by the institutional review boards of the participating institutions and registered with the UMIN Clinical Trials Registry as UMIN 000005176 (<http://www.umin.ac.jp/ctr/>).

Responses were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Progression-free survival (PFS) was defined as the time from initiation of chemotherapy to confirmation of disease progression or death due to any cause. Overall survival (OS) was defined as the time from initiation of chemotherapy to death due to any cause. Surviving patients were censored on their last follow-up date. PFS and OS were estimated using the Kaplan--Meier method and compared with the log-rank test. Among the patients treated with EP or IP, multiple variate analysis by Cox proportional hazard models was performed, and the hazard ratio (HR) and the corresponding 95% confidence interval (95% CI) for OS were calculated, using the following seven variables selected based on the results of previous investigations and our clinical experience: age (\<60 years/≥60 years), sex (male/female), Eastern Cooperative Oncology Group performance status (0--1/≥2), primary site (GI/HBP), liver metastasis (yes/no), prior surgery (yes/no), baseline serum lactate dehydrogenase (LDH) levels (not elevated/elevated), and first-line chemotherapy regimens (EP/IP). Statistical analysis was performed using SPSS software, version 17.0 (SPSS, Chicago, IL, USA).

Results
=======

Patient characteristics
-----------------------

Figure[1](#fig01){ref-type="fig"} represents the study population flow chart. A total of 258 patients satisfied the selection criteria. Their characteristics are shown in Table[1](#tbl1){ref-type="table"}. The majority of patients were male (71%) and the most common primary site was the esophagus (33%) followed by the stomach (27%). Most patients both in the GI (84%) and HBP (88%) subgroups had Stage IV or recurrent disease.

###### 

Patient characteristics

                                       All patients    GI primary    HBP primary
  ------------------------------------ --------------- ------------- ---------------
  Number                               258             192 (74%)     66 (26%)
  Age, years                                                         
    Median (range)                     62.5 (26--81)   63 (26--81)   58.5 (29--78)
  Sex (%)                                                            
    Male                               182 (71)        153 (80)      29 (44)
    Female                             76 (29)         39 (20)       37 (56)
  Performance status (%)                                             
    0 or 1                             240 (93)        176 (92)      64 (97)
    ≧2                                 18 (7)          16 (8)        2 (3)
  Baseline lactate dehydrogenase (%)                                 
    Elevated                           136 (53)        91 (47)       45 (68)
    Not elevated                       95 (37          79 (41)       16 (24)
    No data                            27 (10)         22 (11)       5 (8)
  Chromogranin A staining (%)                                        
    Positive                           172 (67)        122 (64)      50 (76)
    Negative                           59 (23)         51 (26)       8 (12)
    No data                            27 (10)         19 (10)       8 (12)
  Synaptophysin staining (%)                                         
    Positive                           204 (79)        153 (80)      51 (77)
    Negative                           29 (11)         21 (11)       8 (12)
    No data                            25 (10)         18 (9)        7 (11)
  Ki-67 index (%)                                                    
    ≥55%                               43 (17)         20 (10)       23 (35)
    \>20%, \<55%                       27 (10)         18 (9)        9 (14)
    No data                            188 (73)        154 (80)      34 (52)
  Histology (%)                                                      
    PDNEC                              63 (24)         37 (19)       26 (39)
    Small cell carcinoma               122 (47)        99 (52)       23 (35)
    MEEC                               21 (8)          16 (8)        5 (8)
    Clinically diagnosed NEC           52 (20)         40 (21)       12 (18)
  Stage (%)                                                          
    IV or recurrent                    219 (85)        161 (84)      58 (88)
    I--III                             39 (15)         31 (16)       8 (12)
  Primary site (%)                                                   
    Esophagus                          85 (33)         85 (44)       
    Stomach                            70 (27)         70 (36)       
    Small bowel                        6 (2)           6 (3)         
    Colorectum                         31 (12)         31 (16)       
    Hepato-biliary system              31 (12)                       31 (47)
    Pancreas                           35 (14)                       35 (53)
  Location of metastases (%)                                         
    Liver                              136 (53)        95 (49)       41 (62)
    Lymph nodes                        131 (51)        103 (54)      28 (42)
    Lung                               27 (10)         25 (13)       2 (3)
    Bone                               12 (5)          9 (5)         3 (5)
    Brain                              1 (0.4)         1 (0.5)       0 (0)
    Others                             30 (11.6)       26 (14)       4 (6)
  Prior surgery (+) (%)                76 (29)         66 (34)       10 (15)

GI, gastrointestinal tract; HBP, hepato-biliary-pancretic system; MEEC, mixed endocrine-exocrine carcinoma; NEC, neuroendocrine carcinoma; PDNEC, poorly differentiated neuroendocrine carcinoma.

![Flow chart of the study population. CRT, chemoradiotherapy; Cx, chemotherapy; EP, etoposide plus cisplatin; IP, irinotecan plus cisplatin; *n*, number; NEC, neuroendocrine carcinoma; RT, radiotherapy.](cas0105-1176-f1){#fig01}

Treatment
---------

The most common regimen for first-line chemotherapy was IP (*n = *160, 62%), followed by EP (*n = *46, 18%) and fluoropyrimidine-based regimens (*n = *37, 14%), such as 5-fluorouracil/leucovorin/oxaliplatin combination regimen (FOLFOX) and S-1 (Table[2](#tbl2){ref-type="table"}).

###### 

First-line chemotherapy regimens

                                                           Eso   Stm   SB   CR   HB   P    Total (%)
  -------------------------------------------------------- ----- ----- ---- ---- ---- ---- -----------
  Number                                                   85    70    6    31   31   35   258 (100)
  Irinotecan+Cisplatin (IP)                                71    54    2    15   7    11   160 (62)
  Irinotecan+Carboplatin                                   0     0     0    0    1    0    1 (0.4)
  Etoposide+Cisplatin (EP)                                 4     4     2    2    16   18   46 (18)
  Etoposide+Carboplatin                                    2     0     1    1    0    0    4 (2)
  Gemcitabine-based[†](#tf2-1){ref-type="table-fn"}        0     0     0    0    5    5    10 (4)
  Fluoropyrimidine-based[†](#tf2-1){ref-type="table-fn"}   6     11    1    13   3    3    37 (14)
  Others                                                   2     1     0    0    0    0    3 (1)

Overlapped. CR, colorectum; Eso, esophagus; HB, hepato-biliary system; P, pancreas; SB, small bowel; Stm, stomach.

Survival
--------

The median OS of all 258 patients was 11.5 months. In terms of primary site, the median overall was 13.4 months the esophagus, 13.3 months for the stomach, 29.7 months for the small bowel, 7.6 months for the colorectum, 7.9 months for the hepato-biliary system and 8.5 months for the pancreas (Fig.[2](#fig02){ref-type="fig"}). Subgroups were determined by histological analysis and the median OS in months was calculated: PDNEC (12.6, *n = *63), SCC (13.0, *n = *122), MEEC (12.3, *n = *21) and clinically-diagnosed NEC (9.9, *n = *52) (Fig.[3](#fig03){ref-type="fig"}). No statistically significant difference in OS was found between the four histology subgroups, including clinically-diagnosed NEC (*P *= 0.120).

![Kaplan--Meier curves for overall survival according to the primary site. CR, colorectum; Eso, esophagus; HB, hepato-biliary system; OS, overall survival; P, pancreas; SB, small bowel; Stm, stomach.](cas0105-1176-f2){#fig02}

![Kaplan--Meier curves for overall survival according to histology. MEEC, mixed endocrine-exocrine carcinoma; NEC, neuroendocrine carcinoma; OS, overall survival; PDNEC, poorly differentiated neuroendocrine carcinoma; RR, response rate; SCC, small cell carcinoma.](cas0105-1176-f3){#fig03}

Comparison of irinotecan plus cisplatin and etoposide plus cisplatin regimen efficacy
-------------------------------------------------------------------------------------

Among the 258 patients, 206 patients (80%) received either IP or EP as their first-line chemotherapy. Table[3](#tbl3){ref-type="table"} shows the response rate, median PFS and median OS for these 206 patients. In total, 160 patients who received IP showed a better response rate (50 *vs* 28%, *P *\< 0.001), longer PFS (median, 5.2 *vs* 4.0 months, *P *= 0.033) and longer OS (median, 13.0 *vs* 7.3 months, *P *\< 0.001) than 46 patients who received EP. According to primary site, 142 patients (89%) in the GI subgroup received IP while 34 patients (65%) received EP in the HBP subgroup. The response rate of IP was significantly better than that for EP in the HBP subgroup (39 *vs* 12%, *P* = 0.034), but there were no statistically significant differences with respect to response rate, PFS, or OS between IP and EP in the GI subgroup.

###### 

Efficacy comparison IP versus EP

                   IP             EP            *P*-value
  ---------------- -------------- ------------- -----------------------------------------
  Total                                         
    Number         160            46            
    RR             50% (80/160)   28% (13/46)   \<0.001[†](#tf3-1){ref-type="table-fn"}
    PFS (median)   5.2 m          4.0 m         0.033[‡](#tf3-2){ref-type="table-fn"}
    OS (median)    13.0 m         7.3 m         \<0.001[‡](#tf3-2){ref-type="table-fn"}
  GI                                            
    Number         142            12            
    RR             51% (73/142)   75% (9/12)    0.140[†](#tf3-1){ref-type="table-fn"}
    PFS (median)   5.4 m          4.9 m         0.585[‡](#tf3-2){ref-type="table-fn"}
    OS (median)    13.4 m         14.0 m        0.976[‡](#tf3-2){ref-type="table-fn"}
  HBP                                           
    Number         18             34            
    RR             39% (7/18)     12% (4/34)    0.034[†](#tf3-1){ref-type="table-fn"}
    PFS (median)   4.4 m          3.7 m         0.056[‡](#tf3-2){ref-type="table-fn"}
    OS (median)    10.1 m         6.9 m         0.050[‡](#tf3-2){ref-type="table-fn"}

χ2.

Log-rank test. EP, etoposide plus cisplatin; GI, gastrointestinal tract; HBP, hepato-biliary-pancreatic system; IP, irinotecan plus cisplatin; OS, overall survival; PFS, progression-free survival; RR, response rate.

Second-line chemotherapy
------------------------

Following the failure of IP or EP, 116 patients received second-line chemotherapy. The efficacies of second-line chemotherapy according to the regimen and primary site, GI versus HBP, are shown in Table[4](#tbl4){ref-type="table"}. The efficacy of second-line chemotherapy was slightly better in GI than in HBP patients.

###### 

Efficacy of second-line chemotherapy

                 Number   RR (%)   PFS[†](#tf4-1){ref-type="table-fn"} (median)   OS[‡](#tf4-2){ref-type="table-fn"} (median)
  -------------- -------- -------- ---------------------------------------------- ---------------------------------------------
  Regimen                                                                         
    Amrubicin    25       4        1.9 m                                          8.3 m
    EP or CE     23       17       1.9 m                                          5.0 m
    Irinotecan   21       5        2.2 m                                          5.9 m
    S-1          11       27       2.4 m                                          12.2 m
    IP           5        40       4.8 m                                          8.7 m
  Primary site                                                                    
    GI           87       15       2.3 m                                          8.1 m
    HBP          29       0        1.6 m                                          5.1 m
  Total          116      11       2.1 m                                          6.3 m

PFS from second-line chemotherapy.

OS from second-line chemotherapy. CE, etoposide plus carboplatin; EP, etoposide plus cisplatin; GI, gastrointestinal tract; HBP, hepato-biliary-pancreatic system; IP, irinotecan plus cisplatin; OS, overall survival; PFS, progression-free survival; RR, response rate.

Prognostic factors
------------------

In multivariate analysis of prognostic factors for the 206 patients who received EP or IP as their first-line chemotherapy, 23 patients were excluded from the analysis because of no available data on baseline serum LDH levels. The primary site (GI *vs* HBP; HR 0.58, 95% CI 0.35--0.97; *P *= 0.039) and baseline serum LDH levels (not elevated *vs* elevated; HR 0.65, 95% CI 0.46--0.94) were independent prognostic factors for OS (Table[5](#tbl5){ref-type="table"}). There was a tendency towards longer survival in patients treated with the IP regimen, although the difference was not statistically significant (IP *vs* EP; HR 0.80, 95% CI 0.48--1.33; *P *= 0.389).

###### 

Univariate and multivariate analysis for overall survival[†](#tf5-1){ref-type="table-fn"}

                                           Univariate analysis   Multivariate analysis           
  ---------------------------------------- --------------------- ----------------------- ------- -------------------
  Age                                                                                            
    \>60 years old (*vs* \<60 years old)   0.069                 0.73 (0.52--1.03)       0.541   0.89 (0.62--1.28)
  Sex                                                                                            
    Female (*v*s male)                     0.143                 0.76 (0.52--1.10)       0.766   0.94 (0.61--1.43)
  Performance status                                                                             
    0, 1 (*vs* 2≦)                         0.022                 0.49 (0.26--0.90)       0.130   0.55 (0.26--1.20)
  Lactate dehydrogenase                                                                          
    Notelevated (*vs* elevated)            0.002                 0.58 (0.41--0.82)       0.021   0.65 (0.46--0.94)
  Primary site                                                                                   
    GI (*vs* HBP)                          \<0.001               0.48 (0.33--0.70)       0.039   0.58 (0.35--0.97)
  Liver metastasis                                                                               
    (--) (*vs* (+))                        0.033                 0.69 (0.49--0.97)       0.119   0.76 (0.53--1.08)
  First-line chemotherapy                                                                        
    IP (*vs* EP)                           0.001                 0.48 (0.33--0.70)       0.389   0.8 (0.48--1.33)
  Prior surgery                                                                                  
    (+) (*vs* (−))                         0.141                 0.71 (0.45--1.12)       0.636   0.89 (0.55--1.45)

Number = 183 (In analyzing prognostic factors, 23 patients were excluded for whom baseline serum lactate dehydrogenase level data were not available.) CI, confidence interval; EP, etoposide plus cisplatin; GI, gastrointestinal tract; HBP, hepato-biliary-pancreatic system; HR, hazard ratio; IP, irinotecan plus cisplatin.

Discussion
==========

In 2013, the NORDIC group reported a large cohort of GI-NEC patients (NORDIC NEC study) and this study is now regarded as an important reference in the NEC field.[@b16] The current study is also a large-scale study, conducted subsequent to the NORDIC NEC study. Therefore, it is appropriate to compare the major findings of these two recent studies. Both studies indicated that the primary site and baseline serum LDH levels were important prognostic factors. However, survival of pancreatic NEC patients was extremely poor, with a median OS of 8.6 months in our study, compared with the median OS of 15 months in the NORDIC NEC study. This discrepancy could be due to a difference in patient characteristics and/or tumor biology. In our study, 61% of the pancreatic NEC patients had a Ki-67 index ≥55% compared to only 30% for such patients in the NORDIC NEC study. It should be noted, however, that Ki-67 index data were unavailable for almost half (17/35) of the pancreatic NEC patients in our study (data not shown).

First-line chemotherapy regimens were different between the two studies. In our study, IP was the most commonly selected regimen, especially for the GI subgroup, while EP was the most commonly selected regimen in the NORDIC NEC study. This discrepancy might be caused by the different recognition of standard regimens of SCLC between Japan and other countries. In terms of treatment for extensive-stage SCLC, IP demonstrated superiority to EP in a randomized controlled trial conducted in Japan (JCOG9511).[@b17] IP is still considered a standard therapy for extensive-stage SCLC in Japan, although two subsequent randomized controlled trials conducted outside Japan were not able to confirm these earlier results.[@b18],[@b19] Therefore, it is essential to determine which chemotherapy regimen, IP or EP, is more effective for NEC of the digestive system. However, the number of published reports on chemotherapy for advanced NEC is limited, and most articles investigate a small number of patients, especially for those treated with IP.[@b11]--[@b15] The definition of NEC has also changed recently. Thus, it is difficult to arrive at a current consensus of standard treatment for advanced NEC based on previous reports.

Our study is the largest study to compare the efficacy of EP and IP. The efficacy of IP was slightly better than EP for the treatment of NEC, even after adjusting patient background by multivariate analysis. Although it can be expected that IP might bring more favorable outcomes than EP, especially in the HBP subgroup, there was a considerable confounding bias between chemotherapy regimens and primary sites. Indeed, most patients in the GI subgroup received IP whereas most patients in the HBP subgroup received EP primarily because of different treatment policies among the institutions. Consequently, it remains difficult to determine which regimen was more effective and whether the optimal chemotherapy regimen depends on the primary site for treating advanced NEC based on the results of our retrospective analysis. According to the consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials planning meeting, GI-NET and pancreatic NET should be examined separately in clinical trials.[@b20] Although, NET and NEC are different disease entities and there is still no consensus with regard to NEC, prognosis was poorer in pancreatic NEC compared with GI-NEC in the current study. Further study is required to determine the appropriateness of treating all digestive NEC with the same chemotherapy regimen, and whether pancreatic NEC should be investigated separately.

Our analysis indicated only a limited efficacy of second-line chemotherapy. Oral topotecan monotherapy has been recommended for patients with platinum refractory or relapsed SCLC.[@b8],[@b21]--[@b23] Recently, amrubicin was considered a promising regimen in this setting for SCLC, because it significantly improved the response rate compared with topotecan (31 *vs* 17%).[@b24] Based on these more recent results, amrubicin was the most commonly-used regimen for second-line chemotherapy in our study. However, its response rate and median PFS were only 4% and 1.9 months, respectively. Amrubicin does not appear to be a promising treatment for platinum-refractory NEC. It is also necessary to establish effective treatment in the second-line setting for NEC of the digestive system.

The present study had several limitations. First, there was wide variation in the quality of pathological diagnosis. In the 2010 WHO classification, the importance of the Ki-67 index is emphasized in the grading of NEN. However, Ki-67 index information was not obtained for 73% of the patients in the present study because many of the subjects in this study had been treated before the recent WHO criteria were published in 2010. Recently, histological differentiation has been recognized as important for diagnosis of NEC and it is well known that poor differentiation is related to poor prognosis. Moreover, the present study included clinically-diagnosed NEC patients. In practice, there are some unavoidable cases where tumor grades are estimated according to histological differentiation and tumor growth velocity because adequate specimens are unavailable for histological grading, particularly specimens obtained by endoscopic ultrasound-guided fine-needle aspiration. In the present study, the prognoses of clinically-diagnosed NEC patients were as poor as for patients in the other histology subgroups. This finding may be one rationale for treating clinically-diagnosed NEC patients in accordance with the treatment of histologically-diagnosed NEC patients. Second, we did not collect toxicity data. These limitations can only be resolved by a well-designed prospective clinical trial. We are currently planning a randomized phase III trial comparing IP with EP for the treatment of advanced NEC of the digestive system.

In conclusion, IP and EP are the most commonly selected treatment regimens in Japan for NEC of the digestive system. The primary site and baseline serum LDH levels are independent prognostic factors for NEC, and IP showed a slightly better tendency for efficacy compared to EP. A prospective randomized controlled trial is required to establish the most appropriate chemotherapy regimen for advanced NEC of the digestive system.
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